1. Pink Sheet
  2. >>Archive

Spectrum Hopes For Synergies With Allos Acquisition Amid Phase III Setback

 
• By Lisa LaMotta

Spectrum issued a tender offer of $1.82 per share for Allos Therapeutics on the same day that it announced the Phase III failure of its bladder cancer drug.

On the heels of a Phase III failure, Spectrum Pharmaceuticals Inc. has announced April 5 that it will buy specialty cancer outfit Allos Therapeutics Inc. The beleaguered biotechs may have found a match that will make the combined company worth more than the sum of its parts.

Spectrum has agreed to pay $1.82 per share, or $206 million, upfront to Allos shareholders, along with a Contingent Value...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet

MHRA Investigates GLP-1 And Pancreatitis Genetic Link In Personalized Medicine Push

 
• By Eliza Slawther

The UK drug regulator is collecting data to establish whether patients who are hospitalized for acute pancreatitis after taking a GLP-1 drug have a genetic predisposition to this side effect. If a “clear link” is found, the MHRA would consider regulatory action.

Titanium Dioxide Stays: EU Decides Not To Pull Plug On Widely Used Excipient

 
• By Neena Brizmohun

While titanium dioxide is banned as a food additive in the EU, the European Medicines Agency has convinced the European Commission to allow its continued use in the many thousands of medicines in which it is currently used.

US FDA Requires Opioid Class Labeling Changes Despite Adcomm Advice

 
• By Kate Rawson

Quantitative estimates of the safety risks with opioid pain medication, including the risk of addiction and misuse, must be added to labeling.